/l. Bone marrow aspirate showed 15% of blasts and dysplastic characteristics (hypogranular neutrophil precursors, neutrophil Pelger-Hue¨t hypolobulations, dysmegakaryocytic and dyserythropoietic features).
Immunophenotyping analysis detected a CD13
þ MPO þ CD33 þ CD34 À myeloid clone. Cytogenetic analysis on the marrow leukemic cells showed a trisomy 8 in 12 out of the 20 cells examined (Figure 1) , with no structural abnormalities. The diagnosis of refractory anemia with excess of blasts in transformation (RAEB type II) was retained. The patient underwent two courses of standard AML-like chemotherapy consisting of daunorubicin and cytarabine, with a complete cytological and karyotypic remission. After 5 months, she relapsed with strictly similar clinical, cytological (41% of bone marrow blasts), immunophenotypical and cytogenetical characteristics. Since conventional chemotherapy had failed in controlling the disease, and because a full HLA-matched sister was available, in March 2002, the patient received a non-myeloablative allogeneic transplant with her sister's G-CSF-mobilized peripheral blood stem cells, as immunotherapy. Conditioning regimen consisted in 3 days of fludarabine, 2 Gy total body irradiation and cyclosporin þ mycophenolate mofetil as immunosuppressive agents. 5 Molecular chimerism (VNTR analysis) analyzed at day 28 after transplantation was the 93% donor. She developed at day 60 a grade II skin acute GVHD resolved after a short course of steroids. At 3 months after transplantation, the patient relapsed with WBC 10.1 Â 10 9 /l (neutrophils 58%, eosinophils 1%, basophils 2%, monocytes 14%, myelocytes 1%, lymphocytes 9%, blasts 15%) and disseminated intravascular coagulation. The bone marrow aspirate showed 40% polymorphic blasts with a different morphology than that from diagnosis. Megakaryocytic cells showed dysplastic features and were predominantly micromegakaryocytes.
Immunophenotyping analysis showed a similar CD13
þ phenotype, but the acquisition of CD34 expression. The karyotype showed in all 20 analyzed metaphases a Ph resulting from t(9;22)(q34;q11) associated with 5q deletion and other complex rearrangements (Figure 2 ), but there were no metaphases with trisomy 8 or the normal karyotype. FISH analysis using a probe for detection of the Bcr-Abl translocation (LSI BCR/ABL ES Dual Color Translocation Probe, Vysis, Woodcreek, IL, USA) exhibited two fused orange/green signals (5 0 Bcr/ 3 0 Abl) located on the long arms of chromosomes 9 and 22, suggesting a minor breakpoint signal pattern (Figure 3 ). Reverse-transcription and 'real-time' quantitative polymerase chain reaction (RQ-PCR) 6 confirmed this assumption with a p190
Bcr-Abl transcript detected, and no p210 We describe here the first case of a secondary minor BcrAbl Ph occurring after non-myeloablative sibling-donor allogeneic hematopoietic stem cell transplantation, with poor prognosis. Secondary Ph occurring after conventional chemotherapy or autologous hematopoietic transplantations has already been reported a few times in the literature. 1, 3, 4 In myelodysplastic syndromes, the Ph is an unusual finding (19 cases reported to date 4, 7, 8 ), and mostly concomitant with acute transformation of the disease, as in our case. Since we could perform a retrospective analysis by FISH and RTRQ-PCR on the patient and donor's frozen cells along the course of the medical history, we could ensure that (1) the Ph has really been acquired after allogeneic transplantation and was not present at diagnosis, (2) this chromosomal abnormality was developed from recipient cells and not donor cells, and this was particularly important to point out as normal donors can harbor the Bcr-Abl þ translocation, 10,11 (3) the Ph acquisition occurred shortly (3 months) after allogeneic transplantation and it is probably unlikely that conventional chemotherapy given initially (started 9 months earlier) could induce such genetic lesions, as it usually takes much longer time to occur, 9 (4) a different cytological (polymorphic blasts, megakaryocytic dysplastic features), immunophenotypical (CD34 negative ), cytogenetical (Ph and 5q deletion) and molecular (p190 Bcr-Abl transcript) phenotype than that was found from diagnosis. All these last features can be encountered in myelodysplastic syndromes, 4,7 which illustrates here once again the genetic instability that characterizes myelodysplastic syndromes associated with the outgrowth of a new malignant Bcr-Abl þ leukemic subclone enhanced by post transplant immunosuppression. Unfortunately, imatinib mesylate, after an initial response, subsequently failed in long-term control of the disease as in blastic-phase CMLs. 12 In conclusion, this case report illustrates once again the poor prognosis of diseases with secondary Ph þ clones, and that they can be observed after non-myeloablative allogeneic stem cell transplantations, where the context of immunosuppression can certainly favour the Bcr-Abl (q21q32),t(9;22)(q34;q11), del(12)(q21q24),del(13)(q13q32),add(15)(q23), add(16)(q13). The arrows indicate rearranged chromosomes.
